OMGA

Omega Therapeutics Inc

OMGA.US omegatherapeutics.com + Research + Basket
CIK 0001850838
Employees 93
Phone 617 949 4360
Fiscal year end December
IPO Jul 30, 2021
Address 20 Acorn Park Drive, Cambridge, MA, United States, 02140
Price N/A
USD · NASDAQ
52-week range
0.00
0.00
Market Cap
7.90M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.21
Div. Yield
N/A
% Institutions
87.75%
% Insiders
1.67%

1 Year

-97.9%

3 Year

-98.6%

10 Year

-99.7%
Description

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Actions

Add an action for OMGA.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Kaan Certel Ph.D. President, CEO & Director NA
Dr. David A. Berry M.D., Ph.D. Founder 1978
Ms. Barbara Y. Chan CPA Principal Financial Office, Principal Accounting Officer & Chief Accounting Officer 1964
Dr. Jennifer Nelson Ph.D. Chief Scientific Officer NA
Ms. Eva Stroynowski Senior Vice President of Investor Relations & Corporate Affairs NA
Mr. Anthony Mullin Chief People Officer NA
Mr. Charles O'Donnell Ph.D. VP and Head of Computational Genomics & Data Sciences NA
Dr. Joe Newman Ph.D. Senior Vice President of Early Discovery NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
May 01, 2023 Richard A Young N/A Sale 5.00K $8.00 $40.00K SEC
Apr 06, 2023 Richard A Young N/A Sale 5.00K $8.00 $40.00K SEC
Mar 17, 2023 Richard A Young N/A Sale 10.00K $8.00 $80.00K SEC
Feb 27, 2023 Flagship Pioneering Inc. N/A Purchase 3.32M $5.78 $19.21M SEC
Jan 10, 2023 Richard A Young N/A Sale 20.00K $8.00 $160.00K SEC
Sep 14, 2022 Richard A Young N/A Sale 10.00K $8.00 $80.00K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
UBS Group AG 163.90K Dec 31, 2024 0.30% $0.00 5,378.07%
Wells Fargo & Co 18.44K Dec 31, 2024 0.03% $0.00 -21.33%
Barclays PLC 13.28K Mar 31, 2025 0.02% $0.00 0.00%
Steward Partners Investment Advisory, LLC 5.00K Mar 31, 2025 0.01% $0.00 0.00%
Principal Securities Inc 1.37K Mar 31, 2025 0.00% $0.00 0.00%
Royal Bank of Canada 67.00 Dec 31, 2024 0.00% $0.00 0.00%
683 Capital Management LLC 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
BlackRock Inc 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Northern Trust Corp 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Bridgeway Capital Management, LLC 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Citadel Advisors Llc 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Harbourvest Partners, LLC 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Millennium Management LLC 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
BNP Paribas Arbitrage, SA 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Morgan Stanley - Brokerage Accounts 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Blue Owl Capital Holdings LP 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Catalyst Funds Management Pty Ltd 0.00 Dec 31, 2024 0.00% $0.00 -100.00%
Camden Capital Management, LLC 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Long Corridor Asset Management Ltd 0.00 Mar 31, 2025 0.00% $0.00 -100.00%
Advisor Group Holdings, Inc. 0.00 Dec 31, 2024 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Galileo - Biotech Innovation Fund S USD 175.00K 0.32% ▲ 0.00% Nov 30, 2024
2 NT Ext Eq Mkt Indx Fd DC Lend T3 4.14K 0.01% ▲ 0.00% Dec 31, 2024
3 NT Ext Eq Mkt Indx Fd DC Lend T4 4.14K 0.01% ▲ 0.00% Dec 31, 2024
4 NT Quality Small Cap Core 1.53K 0.00% ▲ 0.00% Mar 31, 2025
5 NT Quality SCC US Fund - L 1.53K 0.00% ▲ 0.00% Mar 31, 2025
6 Northern Small Cap Core I 258.00 0.00% ▲ 0.00% Mar 31, 2025

Financial Highlights

▼
Market Cap: $7.90M
EBITDA: $-72.41M
Book Value: $0.21
Earnings/Share: $-1.32
Profit Margin: 0.00%
Operating Margin: -628.64%
ROA (TTM): -25.02%
ROE (TTM): -166.90%
Revenue (TTM): $8.10M
Revenue/Share (TTM): $0.15
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 214.30%

Valuation Metrics

Enterprise Value: $100.44M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 55.37M
Shares Float: 21.73M
% Insiders: 1.67%
% Institutions: 87.75%
Shares Short: 5.21M
Shares Short (Prior Month): 4.95M
Short Ratio: 6.97
Short % Float: 26.91%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$3.09M
Cost of Goods Sold
adjust
$-65.87M
Gross Profit
subtotal
$-62.78M
SG&A
adjust
$-26.19M
R&D
adjust
$-77.17M
Operating Income
subtotal
$-100.26M
Other / Non-Operating Items
adjust
$2.83M
Net Income
subtotal
$-97.43M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about OMGA.US!